You are here

Insights on Drug Costs, Zika, Antibiotics, and More From Dr. David B. Nash

In a wide-ranging interview, Dr. David B. Nash, Dean of the Jefferson College of Population Health, talks with P&T Editor Steve McIver about value-based pricing, the role of pharmacy benefit managers, Zika virus, antibiotic resistance, and much more.

March 2016 interview

More Headlines

BTC Is a Group of Rare Gastrointestinal Cancers With Limited Treatment Options, Poor Outcomes
Study Demonstrates Rapid Response in Patients, and Doesn’t Affect Tamoxifen Efficacy
Prescription App Can Serve As Training, Monitoring, and Reminder Tool
Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection